Is Kezar Life Sciences, Inc. (KZR) a Buy, Sell, or Hold?
NASDAQ : KZR
Kezar Life Sciences, Inc.
$7.29 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 87.92K
- Market Capitalization
- $53.86M
- P/E Ratio
- -1.18
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $7.55
- Year Low
- $3.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $24.46
Company Overview
NASDAQ
Christopher J. Kirk
Biotechnology
Healthcare
KZR
55
US
USD
Liquidity Metrics
0.02
24.46
24.46
23.98
0.00
Sales & Valuation
-$
0.00
0.82
-1.28
-5.72
Profitability
-$7.66
-$56.03M
0.00%
0.00%
-58.35%
-66.52%
P/E Metrics
-1.18
0.05
0.05
Analyst Price Target & Rating
$7.00
$21.00
$5.00
0/5
7 Analysts
4.14%
Financial Health Scores
1.05
3/9
$64.8M
$68M
$2.76M
-$32.42M
Key Metrics (TTM)
-$11.02M
0.00
0.35
24.46
-58.35%
-63.08%
-84.49%
-78.04%
-566 days
Company Executives
| Name | Title |
|---|---|
| Marc L. Belsky | Chief Financial Officer & Secretary |
| John Franklin Fowler | Co-Founder & Director |
| Mark Schiller | Chief Operations Officer |
| Jack Taunton | Co-Founder |
| Christopher J. Kirk | Co-Founder, Chief Executive Officer & Director |
| Pichi Chiang | Senior Vice President & Controller |
Poll Results
No votes yet today — be the first to share your view!
About Kezar Life Sciences, Inc. (NASDAQ:KZR) Stock
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being inve ... stigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Frequently Asked Questions
-
What is the current Kezar Life Sciences, Inc. (KZR) stock price?
-
Kezar Life Sciences, Inc.(NASDAQ:KZR) stock price is $7.29 in the last trading session. During the trading session, KZR stock reached the peak price of $7.55 while $3.53 was the lowest point it dropped to. The percentage change in KZR stock occurred in the recent session was 0.0% while the dollar amount for the price change in KZR stock was $0.
-
KZR's industry and sector of operation?
-
The NASDAQ listed KZR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KZR?
-
Marc L. Belsky | Chief Financial Officer & Secretary
John Franklin Fowler | Co-Founder & Director
Mark Schiller | Chief Operations Officer
Jack Taunton | Co-Founder
Christopher J. Kirk | Co-Founder, Chief Executive Officer & Director -
How many employees does KZR have?
-
Number of KZR employees currently stands at 55. KZR operates from 4000 Shoreline Court, South San Francisco, CA 94080, US.
-
Link for KZR official website?
-
Official Website of KZR is: https://www.kezarlifesciences.com
-
How do I contact KZR?
-
KZR could be contacted at phone #650 822 5600 and can also be accessed through its website. KZR operates from 4000 Shoreline Court, South San Francisco, CA 94080, US.
-
How many shares of KZR are traded daily?
-
The average number of KZR shares traded daily for last 3 months was 87.92K.
-
What is the market cap of KZR currently?
-
The market value of KZR currently stands at $53.86M with its latest stock price at $7.29